The Food and Drug Administration awarded national priority vouchers under the Commissioner’s National Priority Voucher pilot program to two investigational products for their potential to increase access through affordability for American patients, the agency announced. The products are: Merck’s (MRK) Enlicitide decanoate – an oral PCSK9 inhibitor for lowering LDL cholesterol – and Merck’s Sacituzumab Tirumotecan – a trophoblast cell-surface antigen 2-directed antibody-drug conjugate.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- 5 “High-Yield Dividend” Stocks Poised for Growth in 2026
- Merck strikes agreement with U.S. Government, plans DTC program
- Trump announces pacts with nine pharma companies to lower drug prices
- Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports
- Evaxion provides update on MSD collaboration, retains rights of EVX-B2